The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn More
This op-ed is authored by Jenny Goldstein, chief development officer of the American Technion Society.
For anyone who has faced a cancer diagnosis, or watched someone they love go through one, there is a particular anguish that comes with uncertainty. For me, that feeling is deeply personal. My father, an engineer whose love of science and engineering is part of what ultimately brought me to the Technion, went through multiple cancer diagnoses. I know what it is like to watch someone you love confront the questions that come with cancer.
With early-stage breast cancer, the first steps can be relatively clear: testing, diagnosis, and surgery. But then comes a much harder question: Should I undergo chemotherapy?
It is an intensely personal decision. Chemotherapy can be lifesaving for patients who benefit from it. But for others, it may bring significant physical and emotional consequences without improving their outcomes. Many of my closest friends have gone through breast cancer treatment, and I have seen firsthand the toll it can take.
